Lower respiratory tract infection
Drug research and approvals for lower respiratory tract infection: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 33 studies of lower respiratory tract infection are recruiting on ClinicalTrials.gov, and Health Canada has authorized 8 drug trials for it since 2013.
- Recruiting worldwide: 33
- Trials authorized in Canada: 8
- FDA orphan approvals: 0
- EU medicines: 0
Recruiting Now
Newest start dates first, of 33 recruiting on ClinicalTrials.gov ↗- A Clinical Trial of V175 and V175A in Healthy AdultsNCT07855510 · Phase 1 · Merck Sharp & Dohme LLC · starts Oct 21, 2026
- CLARITHROMYCIN TO PREVENT SECONDARY INFECTIONS IN PATIENTS WITH SEPSIS FOLLOWING LOWER RESPIRATORY TRACT INFECTIONS:…NCT07834346 · Phase 3 · Hellenic Institute for the Study of Sepsis · starts Sep 16, 2026
- The Rhinovirus Hospitalization and Investigation of Nasal-airway Omics (RHINO) StudyNCT07342582 · Not reported · University of Wisconsin, Madison · starts Aug 4, 2026
- Optimising Antibiotic Use for Paediatric Lower Respiratory Tract Infections in AfricaNCT07841691 · Not applicable · University of Witwatersrand, South Africa · starts May 27, 2026
- Impact of BioFire FilmArray Pneumonia Panel vs Routine Diagnostics on Antimicrobial Outcomes (DOOR-MAT)NCT07585604 · Not applicable · Hospital de Clinicas de Porto Alegre · starts May 20, 2026
- TREATment of Lower Respiratory Tract Infection in Selected Hospitals in Southern Sri Lanka (TREAT-SL): a Stepped-Wedge…NCT06331364 · Not applicable · Duke University · starts Feb 27, 2026
- Modern Technologies in Lower Respiratory Tract Infections in ChildrenNCT07381790 · Not reported · Helse Møre og Romsdal HF · starts Dec 15, 2025
- A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk…NCT07214571 · Phase 2 · Shionogi · starts Dec 11, 2025
- A Prospective Cohort Study on Endoscopic Features of Upper Gastrointestinal Tract at High Altitude (Zaduo County)NCT07755384 · Not reported · Jilin University · starts Dec 1, 2025
- Impact of a Multimodal Intervention on Antibiotic Prescribing for Respiratory Infections in Primary CareNCT07359287 · Not applicable · University Hospital, Caen · starts Dec 1, 2025
Trials Authorized in Canada
Newest first; search them all in Canada trials| Feb 26, 2025 | A multi center, adaptive, randomized, controlled trial platform to evaluate safety and efficacy of strategies and treatments for hospitalized patients with…Orencia | University Of Minnesota | Pending |
| Aug 10, 2023 | An interventional, phase 1b, randomized, double-blind, sponsor-open, placebo-controlled, multi-center, dose-finding study to evaluate safety, tolerability and…Sisunatovir (PF-07923568) | Pfizer | Closed |
| Sep 29, 2022 | A phase 3, observer-blind, randomized, placebo-controlled study to evaluate the noninferiority of the immune response and safety of the rsvpref3 oa…RSVPREF3 | GSK | Ongoing |
| Apr 27, 2022 | Assessment of qbkpn site-specific immunomodulator (ssi) efficacy in improving innate immune function and reducing all-cause respiratory tract infection…Qbkpn site specific immunomodulator (ssi) | Qu Biologics Inc | Ongoing |
| Jul 23, 2021 | A randomized, double-blind, placebo-controlled phase 3 efficacy study of an ad26.rsv.pref-based vaccine in the prevention of lower respiratory tract disease…VAC18193 (JNJ-64400141/JNJ-64213175 (AD26/PROTEIN pref rsv vaccine)) | Johnson & Johnson | Closed |
| Aug 14, 2019 | A multicenter, randomized, double blind, placebo-controlled, phase 3 study to determine if rtb101 prevents clinically symptomatic respiratory illness in the…Dactolisib (RTB101, BEZ235) | Restorbio Inc | Ongoing |
| Jul 26, 2017 | An open label safety study of inhaled gaseous nitric oxide (gno) for adults with non-tuberculosis mycobacteria infectionNitric oxide | Dr Jeremy Road | Pending |
| Jul 10, 2015 | A phase 2b, parallel-group, double blind, placebo-controlled, multicenter study of syn-004 compared to placebo for the prevention of clostridium difficile…SYN-004 (recombinant modified class a b-lactamase) | Synthetic Biologics, Inc | Ongoing |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA